Combining biomarkers for prognostic modelling of Parkinson's disease.
PRoBaND clinical consortium
J Neurol Neurosurg Psychiatry
MetadataShow full item record
Vijiaratnam, N., Lawton, M., Heslegrave, A. J., Guo, T., Tan, M., Jabbari, E., Real, R., et al. (2022). Combining biomarkers for prognostic modelling of Parkinson's disease.. J Neurol Neurosurg Psychiatry https://doi.org/10.1136/jnnp-2021-328365
BACKGROUND: Patients with Parkinson's disease (PD) have variable rates of progression. More accurate prediction of progression could improve selection for clinical trials. Although some variance in clinical progression can be predicted by age at onset and phenotype, we hypothesise that this can be further improved by blood biomarkers. OBJECTIVE: To determine if blood biomarkers (serum neurofilament light (NfL) and genetic status (glucocerebrosidase, GBA and apolipoprotein E (APOE))) are useful in addition to clinical measures for prognostic modelling in PD. METHODS: We evaluated the relationship between serum NfL and baseline and longitudinal clinical measures as well as patients' genetic (GBA and APOE) status. We classified patients as having a favourable or an unfavourable outcome based on a previously validated model, and explored how blood biomarkers compared with clinical variables in distinguishing prognostic phenotypes . RESULTS: 291 patients were assessed in this study. Baseline serum NfL was associated with baseline cognitive status. Nfl predicted a shorter time to dementia, postural instability and death (dementia-HR 2.64; postural instability-HR 1.32; mortality-HR 1.89) whereas APOEe4 status was associated with progression to dementia (dementia-HR 3.12, 95% CI 1.63 to 6.00). NfL levels and genetic variables predicted unfavourable progression to a similar extent as clinical predictors. The combination of clinical, NfL and genetic data produced a stronger prediction of unfavourable outcomes compared with age and gender (area under the curve: 0.74-age/gender vs 0.84-ALL p=0.0103). CONCLUSIONS: Clinical trials of disease-modifying therapies might usefully stratify patients using clinical, genetic and NfL status at the time of recruitment.
Movement disorders, 1506, parkinson's disease
External DOI: https://doi.org/10.1136/jnnp-2021-328365
This record's URL: https://www.repository.cam.ac.uk/handle/1810/337299